|
Pegaspargase
resources
|
|
|
|
|
|
DRUG INFO
Pegaspargase
Drug Name:
Pegaspargase
Indication: For treatment of acute lymphoblastic leukemia
Pharmacology: In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Oncaspar exploits a metabolic defect in asparagine synthesis of some malignant cells.
Mechanism Of Action: Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.
Drug Category: Antineoplastic Agents
Brand Names/Synonyms: Putative L-asparaginase precursor;L-asparagine amidohydrolase; Oncaspar (Enzon Inc)
Dosage Forms: LIQUID
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Pegylated E. coli L-asparagine amidohydrolase
Chemical Formula: C1377H2208N382O442S17
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00079
CAS Registry Number: 130167-69-0
|
|
|
|
|
|
Pegaspargase News
(When available)
Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 6, 2006
Finanzen.net, ...of therapeutics totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R),ADAGEN(R), and ...
Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 9, 2006
dBusinessNews Newark (press release), ...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ...
|
|
|
